Peptide Science Virginia

Peptide Science Virginia: A Comprehensive Overview of Research, Industry, and Innovation

The Commonwealth of Peptide Science Virginia has cultivated a surprisingly robust and multifaceted peptide science ecosystem. Anchored by world-class research institutions like the University of Virginia (UVA) and Virginia Tech, and supported by a growing network of biotechnology companies and manufacturing infrastructure, Virginia is making significant contributions to the advancement of peptide-based research and therapeutics. This article explores the dynamic landscape of Peptide Science Virginia across the state, from fundamental academic discoveries to commercial applications.

Academic Research and Institutional Leadership

University of Virginia: Pioneering Peptide Engineering and Design

The University of Virginia School of Engineering and Applied Science stands at the forefront of peptide research, with multiple laboratories pushing the boundaries of peptide design, stability, and application.

The Letteri Lab: Engineering Long-Lived Peptides

One of the most significant challenges in peptide therapeutics is their ephemeral nature—Peptide Science Virginia tend to break down quickly in the body. Rachel Letteri, assistant professor of chemical engineering at UVA, and her Ph.D. advisee Vincent Gray have demonstrated a promising approach to overcome this longevity problem by designing mirror images of natural peptides called coiled coils. Coiled coils are helix-shaped peptides found in nearly 10% of proteins in many organisms, playing critical roles in preparing proteins to carry out their jobs.

The team found that engineered coils with strands spiraling in opposite directions showed stronger binding and greater longevity in biological environments compared to natural coiled coils. Mirror-image peptides improve stability because they are not affected by enzymes that accelerate the chemical breakdown of natural peptides. “Peptide Science Virginia are potentially powerful components of medicines, because they’re just fragments of our natural proteins that our bodies can recognize,” Letteri explained. “But one limitation is that they tend to break down quickly, so we need to figure out how to make them more stable”. The research, published in Biomacromolecules, represents an important step toward next-generation therapeutics and biomaterials.

The Bilodeau Lab: AI-Driven Peptide-Surface Interactions

Camille Bilodeau, assistant professor of chemical engineering at UVA, earned a $600,000 CAREER Award from the National Science Foundation to explore the behavior of peptide-covered surfaces. Her project investigates how peptide molecules can be strategically tethered to surfaces and “tuned” for specific functions, with applications ranging from new medicines to water desalination and semiconductor manufacturing.

The challenge is immense: with 20 naturally occurring amino acids, designing even a 10-amino acid peptide presents over a trillion possible combinations. Bilodeau’s team leverages molecular simulations and artificial intelligence to streamline this complex process. Her research group has introduced an integral deep learning model named PepMNet to accelerate peptide-surface design. “When a solution is needed quickly—say for a biohazardous spill that requires remediation, or for the next new drug that can deliver a targeted therapy during an epidemic—with new AI-driven insights, we hope to identify molecular solutions almost instantly,” Bilodeau said.

Other UVA Peptide Research

Additional peptide research at UVA includes the work of Phillip A. Taylor, who focuses on predicting peptide self-assembly and phase transitions for the design of responsive biomaterials via molecular simulations and machine learning. The Lampe Group investigates supramolecular peptide assembly into hydrogel biomaterials for neural tissue engineering. Researchers in the Pires Laboratory, including Ph.D. candidate Rachita Dash, are exploring peptides that can cross complex bacterial cell walls in the fight against infectious diseases.

Virginia Tech: Peptide Therapeutics for Brain Cancer and Wound Healing

Virginia Tech’s Fralin Biomedical Research Institute at VTC has emerged as a powerhouse in peptide therapeutic development.

JM2 Peptide for Glioblastoma

In a study published in Cell Death and Disease, researchers identified a lab-designed peptide known as JM2 that could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. The median survival after diagnosis is just over 14 months, and glioblastoma almost always recurs from treatment-resistant stem cells.

The research team, led by Assistant Professor Samy Lamouille, discovered that connexin 43—a protein that plays a key role in cell-to-cell communication—is strongly associated with microtubules in glioblastoma stem cells. Using JM2, a connexin 43-derived peptide developed by Professor Rob Gourdie that mimics the microtubule-interacting domain of connexin 43, the researchers found that the peptide was toxic specifically for glioblastoma stem-like cells while leaving healthy brain cells unharmed. These findings support JM2 as a promising new peptide-based drug for targeting the glioblastoma stem cells that drive tumor recurrence.

ACT1 Peptide for Wound Healing

Gourdie also developed a wound-healing peptide while researching how electrical signals trigger heartbeats. This peptide, known as ACT1 and commercially as Granexin gel, has shown success in clinical trials for venous leg ulcers, with FirstString Research planning Phase 3 trials for FDA approval.

Additional Virginia Tech Research

Researchers at Virginia Tech’s Department of Chemistry are investigating self-assembled nanostructures from constitutionally isomeric peptides. The university’s Mass Spectrometry Facility offers a wide range of analyses for peptides, proteins, and small molecules, providing both targeted and untargeted analyses.

Virginia Commonwealth University: Peptide Detection and Antiviral Research

Virginia Commonwealth University (VCU) in Richmond is classified as an R1 institution with very high research activity. VCU researchers have developed methods for detecting cysteine-containing peptides using resistive-pulse nanopore sensing systems. The university has also patented antiviral biomimetic peptides that bind coronavirus spike protein and inhibit attachment of the virus to cells.

In a notable clinical application, VCU researchers led by Joseph Reiner demonstrated a urine-based test for early ovarian cancer detection that can simultaneously identify multiple peptides. The method identified and analyzed 13 peptides, including those derived from LRG-1, a biomarker found in the urine of ovarian cancer patients.

Biotechnology Companies: Translating Discovery into Therapy

Virginia hosts a growing number of biotechnology companies focused on peptide-based therapeutics and services.

ReAlta Life Sciences: Clinical-Stage Peptide Therapeutics

Based in Norfolk, ReAlta Life Sciences is a clinical-stage biotech company developing dual-targeting therapeutic peptides that address complement and inflammatory processes. Founded in 2017, the company has raised over $215 million across multiple funding rounds. ReAlta’s therapeutic peptides leverage virus-derived mechanisms to rebalance complement and inflammatory processes in the body.

The company’s lead candidate, pegtarazimod, is a complement-blocking peptide derived from astrovirus biology. In May 2026, ReAlta raised an oversubscribed $40 million financing to complete its Phase II trial of pegtarazimod for hypoxic ischemic encephalopathy (HIE), a serious condition in newborns. ReAlta has filed five patents related to peptides and the complement system.

Onca Bio: Expanding Peptide Library Diversity

Richmond-based Onca Bio is developing Segmented In Vitro Translation (SIVT), a novel approach to expand the diversity of peptide libraries for drug discovery. mRNA display is a method for discovering de novo peptide therapeutics and has been the starting point for several macrocyclic peptide drugs addressing conditions including cholesterol management, cancer radiotherapy, and myasthenia gravis.

Onca Bio’s SIVT technology allows more flexibility to install non-natural amino acids, including those that drive cyclization. By diversifying cyclization positions, the company aims to create mRNA display libraries with diversity at every amino acid position, boosting overall chemical space coverage by an order of magnitude. Onca Bio received its first SBIR award from the NIH in 2025.

Covenant Therapeutics: Small Peptide Analogs

Charlottesville-based Covenant Therapeutics has been awarded SBIR funding for designing safe, potent, and cost-effective small peptide erythropoietin analogs for the treatment of anemias.

Mimotopes: Peptide Synthesis and Innovation

Henrico-based Mimotopes has been an industry leader in peptide synthesis and innovation for over 30 years. The company offers solutions for every stage of drug discovery projects, from synthesis to therapeutics.

RioGin: Improving Peptide Pharmacokinetics

Charlottesville-based RioGin develops peptide therapeutic drugs designed to improve pharmacokinetic properties without negatively impacting pharmacodynamic properties. The company’s proprietary platform technology aims to improve patient quality of life through convenient dosing and reduced side effects.

Peptide Manufacturing and Services

Commonwealth Biotechnologies

Founded in 1992 and based in Richmond, Commonwealth Biotechnologies provides research and development support services within the biotechnology and pharmaceutical sectors, offering fee-for-service solutions aimed at improving drug discovery processes.

StemCellLife

Richmond-based StemCellLife is a leader in novel peptide-based pure synthetic substrates for supporting the culture and growth of human stem cells and primary stem cells.

Syntides

Based in Portsmouth, Syntides specializes in custom synthesis, special amino acid derivatives, and sourcing services.

Supporting Infrastructure and Funding

The Virginia Biosciences Health Research Corporation (Virginia Catalyst) awarded $2.2 million in grants to four life and bioscience projects in the Commonwealth in January 2024. This funding supports the translation of academic discoveries into commercial applications. The state has also invested in research infrastructure, including the Mass Spectrometry Facility at Virginia Tech and core facilities at UVA and VCU.

Conclusion

Virginia has established itself as a significant and growing hub for peptide science, with strengths spanning academic research, biotechnology innovation, and manufacturing infrastructure. The University of Virginia’s pioneering work on mirror-image peptides and AI-driven peptide-surface design, Virginia Tech’s promising peptide therapeutics for glioblastoma and wound healing, and VCU’s contributions to peptide detection and antiviral research collectively demonstrate the state’s research excellence.

The Commonwealth’s biotechnology ecosystem—anchored by companies like ReAlta Life Sciences, Onca Bio, and Covenant Therapeutics—is translating academic discoveries into clinical-stage therapeutics with the potential to address serious unmet medical needs. Supported by state funding mechanisms like Virginia Catalyst and a growing manufacturing infrastructure, Virginia’s peptide science community is well-positioned to continue advancing our understanding of these versatile molecules and their potential to transform medicine. As the field continues to evolve, Virginia’s combination of academic excellence, entrepreneurial spirit, and strategic investment promises to keep the Commonwealth at the forefront of peptide-based biomedical research and development.